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Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS).
One potential therapeutic strategy for MS is to induce regulatory cells that mediate immunological tolerance. Probiotics,
including lactobacilli, are known to induce immunomodulatory activity with promising effects in inflammatory diseases. We
tested the potential of various strains of lactobacilli for suppression of experimental autoimmune encephalomyelitis (EAE),
an animal model of MS.
Methodology/Principal Findings: The preventive effects of five daily-administered strains of lactobacilli were investigated
in mice developing EAE. After a primary screening, three Lactobacillus strains, L. paracasei DSM 13434, L. plantarum DSM
15312 and DSM 15313 that reduced inflammation in CNS and autoreactive T cell responses were chosen. L. paracasei and L.
plantarum DSM 15312 induced CD4
+CD25
+Foxp3
+ regulatory T cells (Tregs) in mesenteric lymph nodes (MLNs) and
enhanced production of serum TGF-b1, while L. plantarum DSM 15313 increased serum IL-27 levels. Further screening of the
chosen strains showed that each monostrain probiotic failed to be therapeutic in diseased mice, while a mixture of the three
lactobacilli strains suppressed the progression and reversed the clinical and histological signs of EAE. The suppressive
activity correlated with attenuation of pro-inflammatory Th1 and Th17 cytokines followed by IL-10 induction in MLNs,
spleen and blood. Additional adoptive transfer studies demonstrated that IL-10 producing CD4
+CD25
+ Tregs are involved in
the suppressive effect induced by the lactobacilli mixture.
Conclusions/Significance: Our data provide evidence showing that the therapeutic effect of the chosen mixture of
probiotic lactobacilli was associated with induction of transferable tolerogenic Tregs in MLNs, but also in the periphery and
the CNS, mediated through an IL-10-dependent mechanism. Our findings indicate a therapeutic potential of oral
administration of a combination of probiotics and provide a more complete understanding of the host-commensal
interactions that contribute to beneficial effects in autoimmune diseases.
Citation: Lavasani S, Dzhambazov B, Nouri M, Fa ˚k F, Buske S, et al. (2010) A Novel Probiotic Mixture Exerts a Therapeutic Effect on Experimental Autoimmune
Encephalomyelitis Mediated by IL-10 Producing Regulatory T Cells. PLoS ONE 5(2): e9009. doi:10.1371/journal.pone.0009009
Editor: Derya Unutmaz, New York University, United States of America
Received September 17, 2009; Accepted January 4, 2010; Published February 2, 2010
Copyright:  2010 Lavasani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was partially financed by grants from the Royal Physiographic Society (Lund, Sweden) and resources provided by Knut och Alice
Wallenbergs Stiftelse (Sweden). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Shahram.Lavasani@med.lu.se
Introduction
Multiple sclerosis (MS) is believed to be a T cell-mediated
inflammatory autoimmune disease directed against myelin or
oligodendrocytes in the central nervous system (CNS) and
considered as one of the most common neurological diseases of
young adults in Europe and North America [1]. Much progress
has been made over the past decade in elucidating the causes of
MS and directing therapies toward improving patient outcomes,
but still there are no optimal therapies available aiming at slowing
the disease progression [2]. Experimental autoimmune encepha-
lomyelitis (EAE) in mice is an established animal model for MS
sharing a number of clinical, genetic and immunological features
with the human disease, which makes it suitable to elucidate the
pathogenesis and devise therapy [3]. Failure or breakdown of
immunological tolerance is believed to result in autoimmune
disorders and CD4
+CD25
+ regulatory T cells (Tregs) have shown
to be pivotal players in the maintenance of immune tolerance [4].
Several studies have indicated their role in the prevention of
autoimmunity in animal models and evidence for disturbed or
dysfunction of Tregs have also been observed in patients with
different autoimmune diseases, including MS [5,6]. Tregs are
developmentally classified into natural, induced or adaptive
populations. Most natural Tregs constitutively express the
interleukin (IL)-2 receptor a chain (CD25), are selected in the
thymus, and their development and function depend on the
expression of the transcription factor forkhead box P3 (FOXP3)
[5]. The mechanism of action of Tregs is not completely
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immunoregulatory cytokines IL-10 and transforming growth
factor (TGF)-b [7,8]. Recent reports have shown that adoptive
transfer of CD4
+CD25
+ Tregs significantly protected against EAE
and decreased CNS inflammation through a mechanism that
involves IL-10 [9,10]. A key function of TGF-b and IL-10 is to
maintain T cell tolerance to self by regulating differentiation and
homeostasis of effector and regulatory T cells [11,12]. Interest-
ingly, it has also been shown that IL-10 expression by T cells is
regulated by IL-27 and TGF-b [13].
Recent studies suggest that an impaired intestinal barrier
function might cause an imbalance between Th1 and Th2
immune responses, which in turn, can trigger autoimmune
processes [14]. Lactobacillus species with probiotic properties are
often also part of the commensal microflora of the intestinal tract
in humans and animals and are generally recognized to confer
beneficial health effects [15]. The immunomodulatory properties
of probiotics have raised a lot of interest in recent years. These
include regulation of intestinal microbial homeostasis, mainte-
nance of the gastrointestinal barrier function, interference with the
ability of pathogens to colonize [16,17,18,19,20,21,22] and finally
modulation of local and systemic immune responses [23]. The
mechanisms underlying these beneficial effects are not completely
understood but have been associated with immunomodulatory
properties of specific probiotic strains [24]. Probiotics can reverse
immunological disturbances by inducing immunoregulatory re-
sponses mediating a control of the balance between pro- and anti-
inflammatory cytokines [25,26]. Reviews of several clinical studies
support that probiotics may represent a capable preventive and
therapeutic strategy for allergic and chronic inflammatory diseases
[24,27]. The anti-inflammatory effect of probiotics has been
attributed to increased production of IL-10 by immune cells in the
lamina propria, Peyer’s patches and the spleen of treated animals
[26,28]. Moreover, recent studies provided evidence that one
effect of probiotics may involve induction of differentiation of IL-
10-dependent, TGF-b-bearing regulatory cells [26,29]. Therefore,
probiotics have emerged as promising candidates for treatment of
inflammatory and autoimmune disorders.
In the present study, we investigated the preventive effects of
five daily-administered potential probiotic strains (two strains of
Lactobacillus (L) paracasei, two strains of L. plantarum and the
traditional yoghurt bacterium L. delbrueckii, subsp. bulgaricus)
comparatively on EAE development in mice. After a primary
screening, three strains, L. paracasei DSM 13434, L. plantarum DSM
15312 and L. plantarum DSM 15313, that efficiently prevented
EAE development were chosen for further evaluation. We found
that the immunosuppressive potential of these probiotic strains was
associated with induction of Tregs and production of IL-4, IL-10
and TGF-b1 in mesenteric lymph nodes (MLNs) and spleen.
Despite a preventive effect on EAE, administration of each
individual strain to mice with established EAE was not capable to
suppress the disease. Previous research works with probiotic strains
have suggested synergistic effects of combinations of probiotic
lactobacilli with specific properties [30,31]. We therefore investi-
gated this using different combination of our chosen lactobacilli
which resulted in a mixture containing all three probiotic
lactobacilli (Lacto-mix). We showed that therapeutic treatment
with this new probiotic mixture successfully reversed established
EAE and demonstrated a unique synergistic effect of these strains
to regulate systemic IL-10 release and induce functional Tregs in,
not only intestinal lymph nodes, but also in the periphery and
CNS of diseased animals. Our results emphasize the usefulness of
the EAE model to select potential probiotic strains to design a
mixture of disease specific probiotics and finally the potential of a
novel probiotic lactobacilli mixture for therapeutic intervention in
inflammatory diseases of the CNS.
Results
Oral Administration of Some Strains of Lactobacillus
Prevents EAE
Targeting the immune response in the periphery has led to a
number of therapies for MS, however the serious side effects of the
drugs have prevented their extensive clinical applications [2].
Although the immunomodulatory potential for some probiotic
strains has been investigated mostly in inflammatory bowel
diseases and allergic disorders, little is known regarding the
desired probiotic properties for extraintestinal autoimmune
diseases, in particular for the treatment of MS. Moreover, many
probiotic preparations have been tested in several laboratories
with diverse and sometimes contradictory results [24]. In order to
examine the ability of probiotic lactobacilli to affect systemic
immune responses by suppressing the T cell-mediated chronic
inflammation in the CNS, five different strains, L. paracasei DSM
13434, L. plantarum DSM 15312, L. plantarum DSM 15313 L.
paracasei PCC 101, L. delbrueckii DSM 20081 or vehicle as control,
were orally administered daily to groups of C57BL/6 mice,
starting 12 days prior to immunization for EAE. We observed that
treatment with L. paracasei DSM 13434, L. plantarum DSM 15312
or L. plantarum DSM 15313 prevented and delayed the onset of the
clinical signs of EAE compared to control mice, although efficient
prevention was most extensive in mice receiving L. paracasei DSM
13434 or L. plantarum DSM 15312 (Fig. 1A). In contrast, treatment
with L. paracasei PCC 101 and L. delbrueckii DSM 20081 had no
effect on the disease development (Fig. 1A).
Due to the fact that activation of autoreactive CD4
+ T cells
followed by specific recruitment into the CNS appears fundamen-
tal for EAE development [32], we further analysed the
proliferative responses and CNS infiltration of disease related T
cells in animals treated with probiotics. Ex vivo analysis of
splenocytes, obtained 25 days after the immunization, showed
significantly decreased MOG-reactive T cell proliferation in
animals fed with L. paracasei DSM 13434, L. plantarum DSM
15312 or L. plantarum DSM 15313 compared to splenocytes from
animals fed with L. paracasei PCC 101, L. delbrueckii DSM 20081 or
control mice (Fig. 1B). These data clearly demonstrated the unique
capacity of the probiotic strains, in particular L. paracasei DSM
13434 and L. plantarum DSM 15312 to ameliorate development of
chronic EAE and a direct correlation in their ability to suppress
the disease-inducing inflammatory T cells. Drastically reduced
infiltration of CD4
+ T cells in CNS tissues of these mice, measured
by immunohistochemical analysis, further demonstrated the
protective effect of these probiotic strains (Fig. 1C).
L. paracasei Treatment Reduces Pro-Inflammatory
Cytokine Expression
The ability of probiotic bacteria to relieve inflammation has in
many studies been related to increased elaboration of regulatory
cytokines in the gastrointestinal tract [23]. In addition, little is
known about their effect on systemic cytokine responses. In order
to investigate the mechanism behind the systemic immunosup-
pressive effect of our probiotic strains, splenocytes isolated from
EAE animals treated with L. paracasei DSM 13434, were examined
for expression of a panel of different cytokines. In vitro analysis of
supernatants collected from MOG-stimulated splenocyte cultures
showed significantly decreased secretion of the pro-inflammatory
cytokines TNF-a and IFN-c from cells of probiotic-treated mice,
at day 25 post immunization, compared to control mice (Fig. 2A
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and TGF-b1, was highly enhanced in spleen cell cultures from L.
paracasei treated animals (Fig. 2C–E). Similar results were also
achieved from splenocytes isolated from L. plantarum DSM 15312
treated mice (unpublished data). Taken together, these data
suggest that the suppressive effect of probiotic treatment on
disease-related peripheral Th1 cells is associated with a shift of
cytokine profile from a Th1 type toward a Th2 type response
(including anti-inflammatory cytokines IL-10 and TGF-b1).
Treatment with a Combination of Three Selected
Probiotic Lactobacilli Reverses Established EAE
We have demonstrated that oral administration of L. paracasei
DSM 13434, L. plantarum DSM 15312, L. plantarum DSM 15313
prevented and delayed the onset of EAE (Fig. 1). We have also
shown that L. paracasei DSM 13434 and L. plantarum DSM 15312
induced release of the Th2 type cytokines IL-4, IL-10 and TGF-b1
in spleen cells from EAE mice (Fig. 2). The major goal of our
approach was to find an appropriate immunosuppressive therapy
in the treatment of MS in patients with already developed clinical
signs or symptoms. Therefore, we tested the therapeutic efficacy of
our probiotic treatments in established EAE. Mice were
individually fed with L. paracasei DSM 13434, L. plantarum DSM
15312, or L. plantarum DSM 15313 every second day, starting 14
days after onset of EAE while a control group received saline. We
observed that oral administration of a monostrain probiotic had
no major effect on disease progression. A representative treatment
with L. paracasei DSM 13434 is shown in Figure 3A. Probiotic
strains exist with a broad spectrum of health improving effects and
a combination of strains with specific properties has been
suggested to induce wider antimicrobial spectrum and stronger
anti-inflammatory effects [30,31]. Thus, we hypothesized that
synergistic beneficial effects may be achieved by treatment with
combinations of the three chosen probiotic strains with protective
properties against EAE. Oral administration with mixture of two
strains (randomly mixed) had no measurable suppressive effect on
established chronic EAE (unpublished data). However, a mixture
of all three strains of L. paracasei DSM 13434, L. plantarum DSM
15312 and L. plantarum DSM 15313 successfully suppressed and
reversed chronic EAE in contrast to the saline fed (Fig. 3A). This
mixture is subsequently referred to as ‘‘Lacto-mix’’ herein.
Further, clinical improvement by treatment with the Lacto-mix
was directly associated with reduced CNS inflammation and
infiltration of disease-related CD4
+ T cells (Fig. 3B–D). In
addition, analysis of the cytokine profile released by spleen cells
isolated from Lacto-mix-treated animals also showed significantly
decreased secretion of inflammatory TNF-a, IFN-c and IL-17 by
MOG-reactive T cells compared to cells from control EAE mice
(Fig. 3E–G). Conversely, production of anti-inflammatory IL-10
was markedly enhanced by MOG-reactive spleen T cells in mice
treated with this probiotic combination (Fig. 3H). IL-4 and TGF-
b1 production by spleen cells in Lacto-mix-treated mice was not
statistically different from that observed in control EAE mice
(unpublished data).
In an attempt to examine the differential adjuvanticity response
to live or killed lactobacilli strains, heat killed Lacto-mix was also
Figure 1. Distinct probiotic strains prevents EAE and suppresses MOG-reactive T cells. C57BL/6 mice received either L. paracasei DSM
13434, L. plantarum DSM 15312, L. plantarum DSM 15313 L. paracasei PCC 101, L. delbrueckii DSM 20081 (10
9 cfu, daily) or vehicle as control, starting
12 days prior to immunization for EAE. (A) The mean clinical score for each group of mice (n=8) is shown. Data are representative of three separate
experiments. (B) Spleen cell cultures from the probiotic-treated or control mice were restimulated in vitro with MOG35–55 peptide. MOG specific T cell
proliferation was conducted with [
3H]thymidine incorporation assay and each bar represents the mean stimulation index (6 SEM) from triplicate
measurements (n=3). (C) Immunohistochemical staining for CD4
+ T cells in sections from spinal cord isolated from L. paracasei DSM 13434-, L.
plantarum DSM 15312-treated and control EAE animals at day 25 of immunization. In the histogram, each bar represents the mean percentage of
stained area (6 SEM). * represents a p-value#0,05.
doi:10.1371/journal.pone.0009009.g001
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was not reproduced and no striking differences on clinical signs of
EAE were observed in treated versus control diseased animals
(unpublished data).
These data indicate that a combination of three live strains of
Lactobacillus (Lacto-mix), with evident inhibitory properties against
EAE, is inducing a synergistic effect regarding the capacity to
induce IL-10, suppression of the inflammatory cytokines and the
therapeutic potential in diseased animals.
Probiotic Treatment Induces Regulatory T Cells in an
IL-10-Dependent Manner
Our findings suggested that a treatment with the Lacto-mix was
therapeutic and induced production of IL-10 in activated T cells
(Fig. 3). There is also accumulated information suggesting that
certain probiotics can act through induction of regulatory T cells
that suppress inflammation-provoking effector cells [23]. In order
to better understand how our chosen lactobacilli strains regulate
the immunosuppressive responses and to investigate whether this
was mediated by IL-10 or regulatory T cells, we further
investigated EAE mice treated with the Lacto-mix including IL-
10-defcient mice. We demonstrated that the therapeutic activity of
probiotics was completely abolished in EAE mice lacking IL-10
(Fig. 4A). Analysis on CD4
+T cells isolated from CNS revealed
drastically decreased amounts of IL-17 producing CD4
+T cells in
wild-type (WT) EAE mice receiving the Lacto-mix which instead
showed a significant upregulation of IL-10 producing CD4
+T cells
(Fig. 4B and C). Since our probiotic treatment inhibited all
inflammatory responses during EAE following the activation of IL-
10, there is an indication that this therapeutic action is inducing
Tregs with suppressor activity during the progression of the
disease. Therefore, we investigated cells isolated from MLNs and
spleen of the Lacto-mix-treated mice and when compared to
control EAE animals, we found a significant increase in percentage
and absolute numbers of CD4
+ cells co-expressing CD25 and
Foxp3 in MLNs of both probiotic treated WT and IL-10 KO, but
only in spleens of WT animals (Fig. 4D).
The accumulation of IL-10 producing Treg cells in CNS of
EAE mice has been shown to be correlated to natural recovery
from the disease [33]. We examined brain tissues isolated from
Lacto-mix-treated WT animals and found significant increased
numbers of Foxp3
+ cells in CNS (mainly localized in the
perivascular cuffs of cerebellum), concomitant to the recovery of
EAE (Fig. 4, E–H). The changes in Foxp3
+ cells in probiotic
treated WT animals were uniquely followed by an increase of
CD4
+Foxp3
+ cells in the spleen of these mice which also correlated
with increased amounts of IL-10 producing CD4
+ cells in the
CNS. These data strongly suggest that our chosen mixture of three
lactobacilli strains induces the generation of activated Treg cells in
the intestinal lymphoid organs and that the emergence of probiotic
induced Tregs in spleen and CNS of diseased animals is dependent
on IL-10.
Probiotic Specific Induction of Cytokines and Tregs
We showed that treatment with L. paracasei DSM 13434, L.
plantarum DSM 15312 or L. plantarum DSM 15313 can prevent
EAE development in mice, but only a combination of all three
lactobacilli resulted in an efficient therapeutic activity when given
to mice with established disease (Fig. 3A). Our results demon-
strated the ability of these strains to modulate both local and
systemic immune responses with a strong potential to suppress
autoreactive effector T cells in the periphery and highlighted the
induction of Tregs and immunoregulatory cytokines IL-10 (Fig. 4).
There is emerging evidence that oral administrations of certain
probiotics are able to induce Tregs locally in the gastrointestinal
tract [23]. It is also known that the function of Tregs depends on
IL-10 and/or TGF-b [34]. These findings raises a question
whether the regulatory T cells, once differentiated in the gut, are
either migrating out to the periphery or the systemic cytokine
release, induced by probiotics, can favor differentiation of
regulatory cell population outside the gut. To investigate whether
there are proportional differences in Treg subsets induced by
different lactobacilli, groups of healthy C57BL/6 mice were fed
with L. paracasei DSM 13434, L. plantarum DSM 15312, L. plantarum
DSM 15313, a combination of all three (Lacto-mix), or vehicle
(control) for 14 days. MLNs and spleen were collected and
analysed for CD4
+ T cell subsets expressing the Treg markers
CD25
+ and Foxp3
+ protein. From analysis of MLNs, we found
significantly increased proportions of Tregs in animals treated with
L. paracasei DSM 13434, L. plantarum DSM 15312 or the Lacto-
mix. Interestingly, analysis of the spleens collected from these
animals showed significant higher frequency of Tregs only in mice
receiving the Lacto-mix (Fig. 5A).
In order to determine whether cytokines released in the
peripheral blood of these probiotic treated mice correlated with
the systemic immunomodulatory effect of the strains, we further
investigated the presence of different cytokines in blood collected
from these mice. Serum samples were analysed for a panel of
cytokines, including IL-10, TGF-b1a n dI L - 2 7b yE L I S A .A
significant increase of IL-10 was only observed in serum samples
from animals treated with the Lacto-mix but not when exposed to
the probiotic monostrains, compared to control mice (Fig. 5B). On
Figure 2. L. paracasei reduces secretion of pro-inflammatory
and promotes secretion of anti-inflammatory cytokines in EAE
mice. (A–E) Spleen cell cultures from probiotic-treated or control mice
were restimulated in vitro with MOG35–55 peptide, supernatants were
collected and the levels of pro-inflammatory Th1 cytokines, TNF-a and
IFN-c, and Th2 cytokines, IL-4, IL-10 and TGF-b1, were determined using
ELISA kits. Data are representative of two experiments. Each bar
represents mean 6 SEM of three samples per group. * represents a
p-value #0,05 and ** a p-value #0,01.
doi:10.1371/journal.pone.0009009.g002
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monostrain probiotic showed significantly increased levels of TGF-
b1i nL. paracasei DSM 13434 and L. plantarum DSM 15312 treated
animals while elevated IL-27 serum levels were only measured in
mice fed with L. plantarum DSM 15313 (Fig. 5C and D). Serum
levels of TNF-a,I F N - c, IL-17 or IL-4 were found to be
undetectable or of no significant difference in probiotic treated
versus control animals (unpublished data). Interestingly, recent
studies have shown that IL-27 limits Th1 and Th2 responses and
enhances IL-10 production by T cells, which can be further
enhanced in presence of TGF-b [35]. These findings suggest a
synergistic effect of the three chosen probiotic strains regarding their
capacity to induce serum IL-10 which seems to be of importance for
emergence of probiotic induced Tregs in the periphery.
The Immunosuppressive Effect of Probiotic Induced
Tregs Is Transferable and IL-10-Dependent
Our data demonstrated that administration of the Lacto-mix
induces IL-10 and support the induction of Treg populations in
lymphoid organs (Fig. 5). To assess the tolerogenic activity of
probiotic induced Treg cells and the significance of their IL-10
expression, we tested whether this effect is transferable to naı ¨ve
mice. WT and IL-10 KO mice were orally fed with Lacto-mix or
vehicle (control) daily, during 14 days. MLN cells from treated
animals were isolated and adoptively transferred into naı ¨ve WT
mice which were induced for EAE one day later. The animals were
then followed for clinical signs of the disease. The result showed that
the EAE symptoms were markedly suppressed in animals which
received MLN cells from WT mice fed with Lacto-mix compared to
those which received MLN cells from control WT mice (Fig. 6A).
To investigate the involvement of Tregs, MLN cells isolated from
Lacto-mix-treated WT mice were subjected to selective depletion of
CD4
+CD25
+ T cell populations before transfer to naı ¨ve recipients
which then were immunized for EAE. Evaluation of these animals
clearly revealed that depletion of CD4
+CD25
+ T cells from the
MLN cell population abolished the suppressive effect on EAE
development (Fig. 6A). To further assess the regulatory activity of
probiotic induced Tregs, purified CD4
+CD25
+ Tc e l lf r o mM L N so f
WT or IL-10 KO mice were adoptively transferred into naı ¨ve WT
mice. As shown in Figure 6A, EAE development in mice receiving
CD4
+CD25
+ T cells from WT probiotic-treated animals was
strongly delayed and suppressed compared to those receiving
CD4
+CD25
+ T cells from treated IL-10 KO or WT control mice.
Additional analysis of these animals showed that serum levels of IL-
10 in mice receiving isolated MLNs or CD4
+CD25
+ Tc e l l sf r o m
probiotic-treated mice were significantly increased compared to
mice receiving MLN cells from treated IL-10 KO mice or control
donors and this effect was completely abrogated in mice receiving
CD4
+CD25
+ T cells depleted MLN cells of probiotic fed WT mice
(Fig. 6B). Taken together, these data provide evidence that IL-10
Figure 3. Administration of three potential probiotic strains suppresses inflammatory autoimmune disorders in mice with
established EAE. C57BL/6 mice were immunized and scored for clinical signs of EAE. The animals were orally treated, starting 14 days after the
onset of EAE, with L. paracasei DSM 13434 (n=18), a mixture of lactobacilli (Lacto-mix) containing L. paracasei DSM 13434, L. plantarum DSM 15312
and DSM 15313 (n=18) or saline (vehicle) as control (n=18). (A) The mean clinical score for each group of mice is shown. Data represent pooled
values from two independent experiments. The presence of infiltrating CD4
+ T cells into the spinal cord parenchyma and perivascular cuffs was
assessed by immunohistochemical staining in sections from (B) control EAE and (C) Lacto-mix-treated animals after 20 days of therapeutic treatment.
(D) In the histogram, each bar represents the mean percentage of stained area (6 SEM) from 5 mice per treatment group. Levels of pro-inflammatory
cytokines (E) TNF-a, (F) IFN-c, (G) IL-17, and (H) anti-inflammatory IL-10 were measured in supernatants of MOG35–55 peptide restimulated spleen cell
cultures from the Lacto-mix-treated (n=3) or control mice (n=3), after 20 days of therapeutic treatment. Data are representative of two experiments.
Each bar represents mean 6 SEM of three samples per group. * represents a p-value #0,05 and ** a p-value #0,01.
doi:10.1371/journal.pone.0009009.g003
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+CD25
+ T cells are involved in the protective effect
induced by treatment with the combination of our three chosen
probiotic strains.
Discussion
Autoimmune diseases, such as MS, may result from the
failure of tolerance mechanisms to prevent expansion of
inflammatory autoreactive T cells. CD4
+ Treg cells are
considered as key mediators in the maintenance of immune
tolerance and potent modulators of T cell-mediated immune




+ Tregs and induced or adaptive Tregs [36].
Many studies suggest the importance of regulatory cytokines IL-
10 and TGF-b in mediating the suppressive activity of Tregs
[13]. Accordingly, the functional impairment and diminished
Foxp3 expression of Treg cells in MS patients [37,38] seem to
be directly correlated with decreased expression of immuno-
suppressor cytokine IL-10 released by T cells [39]. Moreover,
the ability of Treg cells to mediate spontaneous recovery from
an active disease process in EAE and MS patients suggest the
therapeutic potential of a possible restoration of Treg homeo-
stasis [6,33].
Recent interests in the influence of intestinal microflora and gut
barrier function on chronic inflammatory and autoimmune disease
have resulted in efforts to improve the microfloral composition by
using probiotics [14,26,40,41]. There is emerging evidence that
certain probiotic bacterial strains exert anti-inflammatory effects
by the ability to favor induction of IL-10-dependent, TGF-b-
bearing regulatory cells [23,26,28]. Although strain-dependent
effects of probiotics in controlling the inflammatory diseases have
been suggested, the essential molecular mechanism of these
bacteria has not been elucidated yet [42,43]. Therefore, a better
understanding of the protective role of different probiotics may
provide ways to use them to induce regulatory cell responses
sufficient to treat severe systemic autoimmunity.
Figure 4. Probiotic treatment suppresses IL-17 expression and favors Treg emergence in an IL-10-dependent manner. C57BL/6 wild
type (WT) or IL-10-KO mice were immunized and observed for clinical signs of EAE. Fourteen days after the onset of EAE, animals were orally treated
with a mixture of lactobacilli (Lacto-mix) or saline as control. (A) The mean clinical score for each group of mice is shown. Data represent pooled
values from two independent experiments. Histograms show the expression of (B) IL-17 and (C) IL-10 by CD4
+ T cells freshly isolated from the brain of
Lacto-mix-treated WT (thick line), IL-10 KO (dashed line), or saline-treated control mice (thin line), after 20 days of therapeutic treatment. (D) MLNs
and spleens isolated from these animals were analysed by flow cytometry for expression of CD4, CD25 and Foxp3. Presented FACS plots show the
percentage of CD4
+Foxp3
+ cells of the total CD4
+ T cells (numbers in quadrants) in control EAE (top panel), Lacto-mix-treated WT (middle panel), or
IL-10 KO (bottom panel) mice. The presence of infiltrating Foxp3
+ cells into the cerebellum parenchyma and perivascular cuffs was assessed by
immunohistochemical staining of sections from (E) control EAE, (F) Lacto-mix-treated WT, (G) Lacto-mix-treated IL-10 KO. (H) In the histogram, each
bar represents the mean percentage of Foxp3 stained area (6 SEM) from 3 mice per treatment group. Data are representative of two experiments.
* represents a p-value #0,05.
doi:10.1371/journal.pone.0009009.g004
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with novel immunoregulatory properties on chronic CNS
inflammation and designed a unique multispecies combination
of Lactobacillus with a therapeutic potential in established chronic
EAE.
Initially, we tested five different Lactobacillus strains with known
probiotic activity for their ability to protect against EAE. We
found that oral administration of three of these strains, L. paracasei
DSM 13434, L. plantarum DSM 15312 and L. plantarum DSM
15313, prior to immunization, delays the onset and suppresses the
progression of EAE. Our data revealed that the suppressed activity
was associated with reduced inflammation in CNS, down-
regulation of MOG35-55-induced T cell responses and a shift in
production of pro-inflammatory Th1 cytokines toward the
beneficial Th2 type response including IL-4, IL-10 and TGF-b1.
It is well known that EAE is mediated by Th-17 and Th1 cells
secreting pro-inflammatory cytokines, such as IL-17, TNF-a and
IFN-c, while disease recovery is associated with increased levels of
Th2 cytokines IL-4, IL-10 and TGF-b1 [44,45]. These cytokines
are known to suppress EAE by shifting the immune response from
a Th1 to a Th2 response [46,47,48]. Thus, an upregulation of
these cytokines observed in probiotic treated animals seems to
induce a shift towards Th2 lymphocytes which may be one of the
mechanisms of down-regulation of the autoimmune responses. In
addition, IL-10 and TGF-b are potent regulatory cytokines acting
directly on the differentiation and homeostasis of effector and Treg
cells [13,49]. In fact, despite of the Th2 cells, the major source of
IL-10 and TGF-b are Treg populations [50,51]. Therefore, we
investigated the presence of CD4
+CD25
+Foxp3
+ Tregs in naı ¨ve
mice and found that administration of probiotics increased the
numbers of these cells in MLN and spleen. More direct support
was also achieved by showing significantly higher levels of IL-4,
IL-10 and TGF-b1 in probiotic-treated mice.
Thus, it may be suggested that gut exposure to probiotic strains
reduces autoreactive T cell activities by direct or indirect
activation of regulatory CD4
+ T cells. The mucosal environment
of the gut is a unique environment for crosstalk between the
commensal bacteria and the mucosal immune system which seems
to affect immunological tolerance and homeostasis within the gut
for priming of inflammatory T cells but also for activation of
regulatory T cell populations [52]. Although the commensal flora
is known to stimulate the mucosal immune cells, an increasing
amount of evidence suggests that Treg cells induced by commensal
bacteria are actively involved in peripheral tolerance, as well as in
local tolerance but the real mechanism is to be elucidated [52].
Oral tolerance induced by anti-CD3 administration has been
shown to suppress EAE by inducing TGF-b-dependent Tregs in
the gut which inhibit the systemic autoimmune inflammation in
EAE [53]. The concept that probiotics act via the induction of
Treg populations has also been indicated in other inflammatory
models. For example, a mixture of probiotic strains (VSL#3)
ameliorates Th1-mediated murine colitis by inducing TGF-b-
Figure 5. A synergistic combination of probiotics induces Treg cell expansion and systemic IL-10 production. Healthy C57BL/6 mice
were daily fed with L. paracasei DSM 13434, L. plantarum DSM 15312, L. plantarum DSM 15313, a mixture of all three (Lacto-mix) or saline (control)
during 14 days (n=5). MLNs and spleens isolated from these animals were analysed for expression of CD3, CD4, CD25 and Foxp3 by flow cytometry.
(A) The proportion of CD4
+CD25
+Foxp3
+ stained cells was examined on the total gated CD3
+ lymphocytes from MLNs (top) and spleen cells (bottom).
Blood serum from these animals was analysed for different cytokines using ELISA kits. Shown are data from (B) IL-10, (C) TGF-b1 and (D) IL-27 analysis.
Data are mean 6 SEM and representative of two experiments. * represents a p-value #0,05 and ** a p-value #0,01.
doi:10.1371/journal.pone.0009009.g005
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mice by inducing IL-10-producing cells in gut associated lymphoid
tissues (GALT) [26,28]. In fact, the immunosuppressive effect of
probiotics used in these models is likely to occur when applied
early in disease development. VSL#3 contains, in addition to
bifidobacteria, a combination of several species of lactobacilli, in
different proportions. However, little is yet known concerning the
contributions of each strain to the VSL#3-mediated effects.
Indeed, recent reports have emphasised both additive and
synergistic probiotic effects but care has to be taken to explore
each strain specifically to select potential candidates to design a
multispecies and disease specific probiotic mixture [30,31].
A major challenge in the search for an ideal immunotherapy for
MS is that the clinical signs of disease are a consequence of an
already established chronic inflammatory disorder of the CNS
induced by activated immune cells. Considering this fact, a novel
immunotherapy combining maximal efficacy and minimal side
effects seeks to alter these inflammatory responses for treatment or
prevention of the disease. In order to further analyse the
immunosuppressive potential of our chosen probiotic strains on
EAE, mice were immunized with MOG peptide and 14 days after
the onset, when showing severe symptoms of the disease, they were
orally fed with each chosen Lactobacillus. Notably, this approach
was not as effective as our prophylactic treatment. To investigate
possible synergistic effects of a combination of these strains in
suppression of EAE, we repeated the experiment and fed the
highly diseased animals with the mixtures of three chosen
probiotic strains. Treatment with a random combination of only
two different Lactobacillus strains did not induce a sufficient
suppression of the disease. However, a mixture of the three
probiotic strains, L. paracasei DSM 13434, L. plantarum DSM
15312, L. plantarum DSM 15313 (Lacto-mix), successfully inhibited
the progression of EAE and significantly suppressed and reversed
chronic EAE in diseased animals. Concurrently, splenocytes of the
Lacto-mix-probiotic treated mice produced lower levels of
inflammatory cytokines IL-17, TNF-a and IFN-c, but increased
amounts of IL-10, when restimulated in vitro with the autoantigen.
In addition, clinical improvement of EAE mice was directly
associated with suppressed inflammation and reduced amounts of
disease-related CD4
+ T cell infiltrates in CNS of Lacto-mix-
treated mice.
As suggested by other studies it remains possible that probiotics
have several means of exerting anti-inflammatory effects by
improving epithelial cell function and induction of regulatory cells
[23]. Nevertheless, these studies did not elucidate the crosstalk
between the systemic immune responses and mucosal immune
system in gut. Consequently, we analysed cytokine expression in
the blood of probiotic-treated animals to determine any possible
correlation with the disease process. Our results showed a unique
strain-dependent pattern of cytokine formation, where L. paracasei
DSM 13434 and L. plantarum DSM 15312 increased levels of TGF-
b1 in the blood, while L. plantarum DSM 15313 enhanced blood
levels of IL-27. Surprisingly, significantly increased serum levels of
IL-10 were only measured in mice receiving a mixture of all three
probiotic strains. Accordingly, the preventive effect of L. paracasei
DSM 13434 and L. plantarum DSM 15312 against EAE
development can further be explained. The important impact of
TGF-b signalling in restoring the autoreactive T cell responses in
peripheral tissues has already been shown in many studies [11].
Recent observations also suggest that TGF-b induces Foxp3
expression and differentiation of adoptive populations of Treg cells
in peripheral tissues and GALT, in particular, and in excessive
levels TGF-b can expand Tregs to protect against autoimmunity
as it was demonstrated in diabetic NOD mice [13,54].
Furthermore, these studies showed that retinoid acid released by
GALT CD103
+ dendritic cells further promote TGF-b-induced
Treg cell differentiation which provide an important mechanism
in T cell tolerance against commensal bacteria.
On the contrary, L. plantarum DSM 15313 showed to be a
potent inducer of IL-27 in the present study. IL-27 is produced
Figure 6. Probiotic-induced Treg cells suppress EAE in an IL-10-dependent fashion. Naı ¨ve C57BL/6 wild type (WT) or IL-10-KO mice were
treated with either the probiotic Lacto-mix or saline (control) during 14 days. MLN cells were isolated from these animals and administered intravenously
into recipient mice which were immunized for EAE 24 h later. (A) EAE development in recipient mice after adoptive cell transfer of total MLN cells





+ cells (from MLNs of Lacto-mix treated WT mice), isolated CD4
+CD25
+ cells (from MLNs of Lacto-mix treated IL-10 KO mice) (n=325). (B)
Serum levels of IL-10 were measured by ELISA in plasma obtained from recipient animals at 28 days after cell transfer. Data are representative of two
experiments. Each bar represents mean 6 SEM of three samples per group. * represents a p-value #0,05 and ** a p-value #0,01.
doi:10.1371/journal.pone.0009009.g006
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on Th1, Th2, and Th17 cell responses in various infection and
autoimmune disease models [55]. IL-27 has also been shown to
trigger IL-10 production by T cells and this can further be
enhanced in presence of TGF-b [35]. This interesting finding
may explain the observation of increased IL-10 blood levels in
animals treated with the mixture of probiotics. Nevertheless, L.
paracasei DSM 13434 and L. plantarum DSM 15312 are able to
induce IL-10 in peripheral tissues but this may not be sufficient
to increase cytokine levels in blood. In addition, recent studies
on probiotics have revealed that they inhibit the generation of
Th1 cells by promoting the appearance of both tolerance-
inducing, IL-10-producing dendritic cells (DCs) and Treg cells
[29]. IL-10 has been considered as a main anti-inflammatory
cytokine with various effects on different cell populations [12].
Antigen stimulation in presence of this cytokine has been shown
to favor IL-10 and TGF-b producing cells with immunoregu-
latory potentials on inflammatory disorders like EAE [56].
Taken together, we suggest that the additive and synergistic
effect of our probiotic mixture can reveal an interrelation
between TGF-b induced by L. paracasei DSM 13434 and L.
plantarum DSM 15312 and IL-27 triggered by L. plantarum DSM
15313 to enhance promotion of IL-10 release by multiple cell
types including Treg cells with potential to induce peripheral
tolerance and suppress ongoing inflammation.
Our study further suggests that the therapeutic effect of oral
administration of probiotic is achieved through an IL-10-
dependent induction of Tregs. In fact, we were able to prevent
EAE in mice by transferring CD4
+CD25
+ cells from the probiotic
Lacto-mix treated WT mice, but not IL-10 deficient one, showing
that probiotic-induced Tregs are tolerogenic once expressing
functional IL-10. We also found that animals receiving MLNs
from Lacto-mix-treated mice showed increased levels of IL-10 in
serum. The connection between the protective activity and Treg
cells was further supported by the fact that depletion of CD4
+
CD25
+ T cells from the MLN cell population removed the
suppressive effect, as well as, excessive serum cytokine levels of IL-
10, in EAE recipients.
One issue that remains to be discussed is the strain specific
differences on the effect of our probiotic bacteria in EAE. The
Lacto-mix strains have previously been isolated from the intestinal
mucosa of healthy humans and have been chosen on the basis of
their pronounced ability to attach to human mucosa cells [57,58].
In contrast to L. paracasei and L. plantarum DSM 15313, the L.
plantarum DSM 15312 strain binds to epithelial cells via a mannose-
dependent mechanism [59]. In addition, a presence of live bacteria
in the gut seems to be essential for their immunomodulatory effect
since the killed bacterial strains used in our study had no
suppressive effect on diseased animals. Our data highlight a major
difference even between strains of the same species and the
importance of selection of disease specific strains and design a
combination of strains with desired properties.
Taken together, we report for the first time that Tregs
induced in the gut are able to suppress inflammatory conditions
in the periphery, even in the CNS, via an IL-10-dependent
mechanism. Thus, induction of Tregs appears to be an
important goal of immunotherapy of autoimmune diseases.
Our study also provides better understanding of the remarkable
immunomodulatory activities of probiotics and a potent
synergistic immunosuppressive effect of different probiotic
strains for treatment of chronic CNS inflammation which,
along with the absence of side-effects, may present a powerful
therapeutic approach in the treatment of autoimmune diseases,
in general, and MS, in particular.
Materials and Methods
Mice
Female C57BL/6 and IL-10-deficient mice on C57BL/6
background (8–10 weeks old) were obtained from Jackson
Laboratories (Bar Harbor, ME). The mice were housed in groups
in polycarbonate cages with free access to a standard diet and tap
water in our animal facility. The trials followed the European
Community regulations for animal experiments and were
approved by the local Ethical Review Committee for Animal
Experiments: Lund’s Tingsra ¨tt.
Induction and Assessment of EAE
A synthetic peptide from myelin oligodendrocyte glycoprotein
(MOG), amino acids 35–55 (MEVGWYRSPFSRVVH-
LYRNGK-COOH, Schafer-N, Denmark) was used to induce
EAE. Mice were immunized by an intradermal injection at the
base of the tail with 0.1 ml of an emulsion containing 100 mg
peptide in complete Freund’s adjuvant (H37RA, Difco laborato-
ries, USA), and were injected i.p. with 400 ng of pertussis toxin
(Sigma-Aldrich, Sweden) on days 0 and 2. The mice were weighed
and examined for clinical signs of EAE in a blinded fashion daily.
The signs of EAE were scored into eight categories: 0- no signs of
clinical disease; 1- weakness in the tail; 2- paralyzed tail; 3- paresis
and gait disturbance; 4- paralysis of one limb; 5- paralysis of two
limbs; 6- two limbs paralyzed and paresis of a third limb, but the
mouse still able to move forward; 7- quadriplegia, no mobility and
moribund state; 8- dead. Food was placed on the cage floor when
a mouse showed a score of 5 or higher. To avoid dehydration,
mice scored with 6 were subcutaneously given 0.5 ml of
physiologic saline solution. When a mouse was scored with 7, it
was sacrificed for ethical reasons. At the end of the experiments,
the animals were anesthetized, bled by heart puncture and
different organs were dissected.
Bacterial Strains and Treatment
Lactobacillus paracasei, DSM 13434 (=8700:2); Lactobacillus
plantarum, DSM 15312 (HEAL9); Lactobacillus plantarum, DSM
15313 (HEAL19); Lactobacillus paracasei, PCC (Probi Culture
Collection) 101 and Lactobacillus delbrueckii, subsp. bulgaricus, DSM
20081 (all strains were provided by Probi AB, Lund, Sweden).
Prophylactic treatment (12 days before the immunization and
throughout the experiment): Mice received regular tap water
(100 ml in flasks) with the bacteria added to a final concentration
of 10
9 colony-forming units/ml (cfu/ml), while control mice only
received tap water. Each mouse drank approximately 5 ml water/
day. After the onset of EAE, each animal was fed daily, via an
intragastric stainless steel feeding tube, with 200 ml of lactobacilli
(10
9 cfu) or sterile physiological saline (control). The dose of 10
9
viable cells was chosen as the optimal dose for these investigations
and comparable to other probiotic studies in rodents and humans
(10
6–10
12 cfu/day). Therapeutic treatment: Two weeks after disease
onset, animals were fed via an intragastric feeding tube with 200 ml
of bacterial strains (10
9 cfu) or saline (control). The diseased
animals were only treated every second day to minimize the stress
induced by the oral gavage treatment. Instead of live bacteria,
groups of animals received a mixture of heat-killed (in sterile
normal saline at 100uC for 30 min) bacteria.
In Vitro T Cell Proliferative Response
Spleens and MLNs were harvested and passed through a cell
strainer (BD Biosciences, USA). Cell suspensions from spleens were
treated with 0.84% NH4Cl to lyse the red blood cells. Isolated cells
were cultured in round-bottom 96-well culture plates (5610
5/well)
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purified protein derivate (PPD) from Mycobacterium tuberculosis
(Statens Serum Institut, Denmark) as the positive control, at
10 mg/ml (all in triplicates), for 72 h with additional 16 h after
addition of 1 mCi of [
3H]thymidine. Cells were then harvested and
counts per minute (CPM) were determined by a gas-flow beta
counter (Matrix 96 Direct beta counter; Packard, USA).
Stimulation index was calculated by dividing the MOG35–55-
specific proliferation by proliferation in cultures with medium only.
ELISA for Cytokine Detection
Cytokine concentrations were measured in serum or superna-
tants from spleen and MLN cell cultures after in vitro challenge
with either 50 mg/ml MOG35–55 peptide (cells from immunized
mice) or 0.5 mg/ml anti-CD3e (clone 145-2C11, BD Biosciences,
USA) monoclonal antibody (cells from non-immunized mice)
using commercially available specific ELISA kits. Supernatants
were collected after 48 h for measurement of TNF-a, IFN-c, IL-4,
IL-10 (BD OptEIA
TM ELISA Sets, BD Biosciences, USA), IL-17A
(R&D Systems, UK) and after 72 h for measurement of TGF-b1
and IL-27p28 concentrations using the quantikine kits (R&D
Systems, UK). The absorbance was measured in an ELISA reader
(Spectra Max M2, Molecular Devices, USA). The cytokine
content in supernatants was determined when data were within
the linear region of the standard curve calculated from values of
the recombinant cytokines.
Analysis by Flow Cytometry
At the end of each experiment MLNs, spleen and brain were
dissected. Single cell suspensions were obtained from MLN and
spleen. Brain mononuclear cells were isolated by Percoll gradients
as described [33]. Cells were incubated with anti-CD16/CD32
followed by APC/FITC/PE-labelled monoclonal antibodies
(mAbs) directed to different murine cell surface markers including
CD3, CD4 and CD25 (all purchased from BD Biosciences, USA).
Foxp3 was analysed using the PE anti-mouse Foxp3 Staining Set
(eBioscience, USA). For analysis of intracellular IL-10 and IL-17A,
immune cells were fixed with Cytofix/Cytoperm solution and
stained with APC-labelled mAbs directed to different cytokines,
(BD Biosciences, USA). Flow-cytometric analysis was performed
according to standard settings on a FACSort flow cytometer
(Becton Dickinson, USA).
Immunohistochemistry
Cryosections from the lumbar region of spinal cord were
prepared, fixed in acetone, blocked for endogenous avidin/biotin
activity (Vector, USA) and incubated with the primary antibody,
rat anti-mouse CD4 (BD Biosciences, USA), for 1 h. The
secondary antibody, a biotinylated goat anti-rat IgG (Jackson’s
Immunoresearch, USA) was applied for 30 minutes. After
incubation in streptavidin-biotin/peroxidase (Dako, Denmark)
for 30 minutes, the immunoreaction was developed in diamino-
benzidine (Sigma-Aldrich, Sweden) and the sections were
counterstained in haematoxylin.
Brain tissue, including medulla oblongata, was sampled by
dividing the organ midsagitally and sectioned parallel to the
midline, fixed in 4% formalin, dehydrated, embedded in paraffin,
and sectioned at 4 mm. The sections were deparaffinised and
incubated with primary antibody rat anti-mouse Foxp3
(eBioscience, CA). Further staining was performed using ‘‘En-
Vision
TM FLEX, High pH visualization kit’’ and ‘‘Dako
Autostainer Plus’’ (Dako, Copenhagen, Denmark). The degree of
leukocyte infiltration was calculated by using a PC-based image
analysis system (Leica Q500, Cambridge, UK). With this
equipment, the area of stained ‘‘positive’’ cells was measured and
compared to the entire analysed area, as described previously [60].
Adoptive Transfer of MLN Cells
Naı ¨ve female C57BL/6 wild type (WT) or IL-10-deficient (KO)
mice were fed with either lactobacilli or sterile saline as described
above during 14 days. MLNs were collected and single cell
suspensions were prepared and washed extensively. 3610
5 cells
were then administered intravenously into recipient mice. EAE
was induced 24 hours later and the animals were scored for
clinical symptoms as mentioned above. In some experiments,
CD4
+CD25
+ T cells were isolated using a MACS CD4
+CD25
+
Regulatory T cell Isolation Kit (Miltenyi Biotech, Germany),
performed according to manufacture’s instructions.
Statistical Evaluations
Statistical evaluation was performed using StatView software
(SAS, Cary, NC, USA). Student’s t test was used to analyze the
significance of results. Mann-Whitney was used for analyzing
differences in clinical scores.
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